Ariceum Therapeutics (Ariceum), a biotech company specializing in the development of radiopharmaceutical products for the diagnosis and treatment of challenging cancers has announced the inauguration of its new laboratory facilities at its Berlin headquarters on March 7. 

These cutting-edge facilities are dedicated to advancing the company's next-generation radiopharmaceutical pipeline candidates and facilitating the transition of emerging products into clinical trials.

The newly opened laboratory provides Ariceum with over 200m² of dedicated space, comprising cold biology/chemistry and radioactive labs, with the potential to expand by an additional 60m² for changing lock and storage requirements. 

Equipped to handle positron emission tomography (PET) and single-photon emission computed tomography (SPECT) isotopes for imaging, as well as beta and alpha isotopes for therapy, the facility empowers Ariceum to conduct on-site process development, method validation, formulation studies, and preliminary stability analysis of radiolabeled compounds. Moreover, it facilitates non-clinical pharmacology studies for in-depth characterization of the company's first-in-class development candidates.

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, expressed his enthusiasm about the completion of the 15-month construction project, stating, "We are delighted to have opened our brand new, advanced laboratory space in Berlin. Since our inception in 2021, Ariceum has made significant strides in expanding our team and advancing the development of next-generation, targeted radiotherapeutics. However, until now, we have relied on external radio pharma facilities. With our new laboratory, we gain internal capabilities not only to drive forward the development of our lead radiopharmaceutical candidates but also to establish a state-of-the-art research hub for R&D collaborations and the identification of promising pipeline candidates. We extend our gratitude to our Berlin team for their dedication in bringing these construction plans to fruition."

With enhanced research capabilities and a commitment to innovation, Ariceum is poised to make substantial contributions to the field of radiopharmaceuticals and improve outcomes for patients battling challenging cancers.